Publications by authors named "Juan M Garzon-Dangond"
Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies.
Cardiooncology
December 2024
Background: CD19 CAR T-cell therapy is a novel anti-cancer treatment that has produced remarkable responses in relapsed or refractory B-cell hematological malignancies. Cytokine Release Syndrome (CRS) is a dysregulated immune response that frequently occurs after CAR T-cell infusion. It can cause cardiac dysfunction and circulatory collapse negatively impacting outcomes and survival.
View Article and Find Full Text PDFArticle Synopsis
- - IL-6 inhibitors are emerging as effective treatments for non-infectious uveitis (NIU) that doesn't respond well to standard therapies, addressing key issues like inflammation and vision loss.
- - Review studies highlight that these biologic agents have succeeded in reducing inflammation in 34% to 88% of patients and decreasing dependency on corticosteroids by about 55%.
- - Although results are promising, showing improvements in visual acuity and macular edema, more research is necessary to confirm the long-term safety and effectiveness of IL-6 inhibitors in uveitis management.
Clinical Relevance: Glaucoma encompasses a group of eye diseases that progressively damage the optic nerve, leading to vision loss and blindness. Understanding the incidence and demographic distribution is vital for public health planning and patient care.
Background: Previous small-scale studies in Colombia have reported the prevalence of glaucoma in individuals over 40 years between 1.
Purpose: To estimate the incidence of Optic Neuritis (ON) in Colombia using data from the national health registry between January 1, 2015, and December 31, 2020.
Methods: A population-based study was conducted using the Integrated Social Protection Information System from the Colombian Ministry of Health and the International Classification of Diseases-10 code for ON to estimate the incidence of ON from 2015 to 2020. We also evaluated the impact of the COVID-19 lockdown on the epidemiology of the disease in 2020.